Rekvina Laboratories Limited Stock

Stocks

VINRKLB

INE092O01028

Market Closed - Bombay S.E. Other stock markets 06:00:58 2026-07-10 EDT			5-day change	1st Jan Change
35.00 ^INR	-2.78%		+4.95%	+677.78%

05-21	Rekvina Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
03-15	Rekvina Laboratories Limited entered into agreement to acquire Radiant Parenterals Limited from Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel, Krima Surbhit Shah and Ami Amit Shah for approximately INR 140 million.	CI

Valuation: Rekvina Laboratories Limited

Market Cap	218M 2.28M 2M 1.85M 1.71M 3.24M 3.29M 22.05M 8.64M 107M 8.58M 8.39M 370M	P/E 2024	-167x	P/E 2025	-19.6x
Enterprise Value	220M 2.31M 2.02M 1.86M 1.72M 3.27M 3.32M 22.27M 8.72M 108M 8.67M 8.48M 373M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	-	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Rekvina Laboratories Limited

Dynamic Chart

Latest news : Rekvina Laboratories Limited

05-21	Rekvina Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
03-15	Rekvina Laboratories Limited entered into agreement to acquire Radiant Parenterals Limited from Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel, Krima Surbhit Shah and Ami Amit Shah for approximately INR 140 million.	CI
03-15	Surbhit Mukesh Shah and Amit Mukesh Shah, the directors of Rekvina Laboratories Limited and Dhruvalkumar Patel proposed to acquire an additional 47.94% stake in Rekvina Laboratories Limited for INR 28.9 million.	CI
03-10	Rekvina Laboratories Limited announced that it expects to receive INR 4.6 million in funding	CI
02-06	Rekvina Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
01-29	Rekvina Laboratories Limited Announces the Resignation of Chetanbhai Jayantibhai Patel as Non- Executive Independent Director and from Membership in Various Committees, Effective from 29 January 2026	CI
01-09	Rekvina Laboratories Limited Announces Resignation of Dhruvalkumar Jayantilal Patel as Non-Executive Independent Director, Effective January 9, 2026	CI
11-14	Rekvina Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
25-09-20	Rekvina Laboratories Limited Announces Shifting of the Registered Office	CI
25-08-13	Rekvina Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-08-04	Rekvina Laboratories Limited Approves Shifting of the Registered Office	CI
25-05-30	Rekvina Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	CI
25-01-20	Rekvina Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI

More news

Quotes and Performance

1 day	-2.78%
1 week	+4.95%
Current month	+2.04%
1 month	-13.81%
3 months	-10.46%
6 months	+677.78%
Current year	+677.78%

More quotes

Course Extremes

1 week	31.69	36
1 month	31.69	39.01
Current year	6.75	46.65
1 year	6.75	46.65
3 years	6.75	46.65
5 years	3.75	46.65
10 years	3.6	46.65

More quotes

Managers and Directors: Rekvina Laboratories Limited

Manager	Title	Age	Since
Amit Mukeshbhai Shah CEO	Chief Executive Officer	44	2024-05-21
Surbhit Shah DFI	Director of Finance/CFO	42	2024-09-01
Deepak Khandelwal CMP	Compliance Officer	-	2024-12-03

Director	Title	Age	Since
Amit Mukeshbhai Shah BRD	Director/Board Member	44	2000-07-31
Nilesh Harkesh Yadav BRD	Director/Board Member	24	2024-05-21
Surbhit Shah BRD	Director/Board Member	42	2024-09-01

More insiders

Financials

	2024	2025
Net sales	-	-
Net income	-164K -1.72K -1.51K -1.39K -1.28K -2.43K -2.47K -16.59K -6.5K -80.76K -6.46K -6.32K -278K	-1.37M -14.37K -12.59K -11.61K -10.73K -20.35K -20.68K -139K -54.33K -675K -53.97K -52.8K -2.33M
Net Debt	798K 8.37K 7.33K 6.76K 6.25K 11.85K 12.04K 80.74K 31.62K 393K 31.41K 30.73K 1.35M	2.22M 23.26K 20.37K 18.79K 17.36K 32.93K 33.46K 224K 87.89K 1.09M 87.31K 85.42K 3.76M